---
pmid: '23597563'
title: Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule,
  allosteric inhibitor of FGF receptor signaling.
authors:
- Herbert C
- Schieborr U
- Saxena K
- Juraszek J
- De Smet F
- Alcouffe C
- Bianciotto M
- Saladino G
- Sibrac D
- Kudlinzki D
- Sreeramulu S
- Brown A
- Rigon P
- Herault JP
- Lassalle G
- Blundell TL
- Rousseau F
- Gils A
- Schymkowitz J
- Tompa P
- Herbert JM
- Carmeliet P
- Gervasio FL
- Schwalbe H
- Bono F
journal: Cancer Cell
year: '2013'
full_text_available: false
doi: 10.1016/j.ccr.2013.02.018
---

# Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling.
**Authors:** Herbert C, Schieborr U, Saxena K, Juraszek J, De Smet F, Alcouffe C, Bianciotto M, Saladino G, Sibrac D, Kudlinzki D, Sreeramulu S, Brown A, Rigon P, Herault JP, Lassalle G, Blundell TL, Rousseau F, Gils A, Schymkowitz J, Tompa P, Herbert JM, Carmeliet P, Gervasio FL, Schwalbe H, Bono F
**Journal:** Cancer Cell (2013)
**DOI:** [10.1016/j.ccr.2013.02.018](https://doi.org/10.1016/j.ccr.2013.02.018)

## Abstract

1. Cancer Cell. 2013 Apr 15;23(4):489-501. doi: 10.1016/j.ccr.2013.02.018.

Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, 
allosteric inhibitor of FGF receptor signaling.

Herbert C(1), Schieborr U, Saxena K, Juraszek J, De Smet F, Alcouffe C, 
Bianciotto M, Saladino G, Sibrac D, Kudlinzki D, Sreeramulu S, Brown A, Rigon P, 
Herault JP, Lassalle G, Blundell TL, Rousseau F, Gils A, Schymkowitz J, Tompa P, 
Herbert JM, Carmeliet P, Gervasio FL, Schwalbe H, Bono F.

Author information:
(1)E2C and LGCR-SDI Department, Sanofi Research and Development, 31100 Toulouse, 
France.

Erratum in
    Cancer Cell. 2016 Jul 11;30(1):176-178. doi: 10.1016/j.ccell.2016.06.015.

The fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) 
signaling network plays an important role in cell growth, survival, 
differentiation, and angiogenesis. Deregulation of FGFR signaling can lead to 
cancer development. Here, we report an FGFR inhibitor, SSR128129E (SSR), that 
binds to the extracellular part of the receptor. SSR does not compete with FGF 
for binding to FGFR but inhibits FGF-induced signaling linked to FGFR 
internalization in an allosteric manner, as shown by crystallography studies, 
nuclear magnetic resonance, Fourier transform infrared spectroscopy, molecular 
dynamics simulations, free energy calculations, structure-activity relationship 
analysis, and FGFR mutagenesis. Overall, SSR is a small molecule allosteric 
inhibitor of FGF/FGFR signaling, acting via binding to the extracellular part of 
the FGFR.

Copyright Â© 2013 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.ccr.2013.02.018
PMID: 23597563 [Indexed for MEDLINE]
